Search for "azepine" in Full Text gives 24 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2025, 21, 935–944, doi:10.3762/bjoc.21.76
Graphical Abstract
Figure 1: D–A–D organic PCs previously reported and our new D–A bimodal organic PCs.
Figure 2: Selected frontier MOs and relative calculated energies of D–A photocatalysts (4a,5a–e, and 6a). Abs...
Figure 3: Comparison of the ground state redox potential of the acceptor moieties (4–6), the donor moieties (a...
Beilstein J. Org. Chem. 2025, 21, 807–816, doi:10.3762/bjoc.21.64
Graphical Abstract
Figure 1: Basic principle of the NBD to QC conversion and vice versa. The bridge-atom at position 7 was varie...
Scheme 1: Synthetic procedure towards new X-NBD derivatives C-NBD1, O-NBD1 and N-NBD1. 1-((Bromoethynyl)sulfo...
Figure 2: Conversion of O-NBD1 to O-QC1 using a 275 nm LED. The UV–vis spectrum was recorded in MeCN; b) the ...
Figure 3: Rearrangement of O-NBD2 to O-QC2 using a 385 nm LED. The UV–vis measurement in the middle were cond...
Figure 4: Rearrangement of N-NBD2 using a 385 nm LED. The UV–vis measurement in the middle were conducted in ...
Beilstein J. Org. Chem. 2023, 19, 1923–1932, doi:10.3762/bjoc.19.143
Graphical Abstract
Scheme 1: Representative [4 + 3] cycloaddition reactions of MBH carbonates derived from isatins.
Scheme 2: Synthesis of spiro[indoline-3,5'-[1,2]diazepines] 3a–m. Conditions: α-halogenated acylhydrazone (0....
Scheme 3: Synthesis of spiro[indoline-3,5'-[1,2]diazepines] 5a–g. Conditions: α-halogenated acylhydrazone (0....
Scheme 4: Synthesis of dihydrospiro[indoline-3,5'-[1,2]diazepines] 7a–n. Conditions: α-halogenated N-tosylhyd...
Figure 1: Single crystal structure of the spiro compound 7a.
Scheme 5: Proposed reaction mechanism.
Scheme 6: Gram-scale synthesis of compound 7c.
Beilstein J. Org. Chem. 2023, 19, 736–751, doi:10.3762/bjoc.19.54
Graphical Abstract
Scheme 1: Construction of HBC by Scholl reaction from hexaphenylbenzene.
Scheme 2: Synthesis of seco-HBC-based chiral nanographenes.
Scheme 3: Synthesis of nitrogen-doped, seco-HBC-based chiral nanographenes.
Scheme 4: Synthesis of π-extended [7]- and [9]helicene containing chiral nanographenes.
Scheme 5: Synthesis of “HBC-dimer”-based chiral nanographenes.
Scheme 6: Synthesis of “HBC-dimer”-based chiral nanographenes.
Scheme 7: Synthesis of axis-based chiral nanographenes.
Scheme 8: Synthesis of “HBC-trimers”-based nanoribbons.
Scheme 9: Synthesis of “HBC-trimers”-based, triangle-shaped chiral nanographenes.
Scheme 10: Synthesis of “HBC-trimers”-based, triangle-shaped chiral nanographenes.
Scheme 11: Synthesis of HBC-based multilayer nanographenes.
Scheme 12: Synthesis of a chiral nanographene constructed by “HBC-tetramers”.
Scheme 13: Synthesis of a triskelion-shaped nanographene constructed by four HBCs.
Scheme 14: Synthesis of a three-dimensional nanographene bearing four HBCs.
Scheme 15: Synthesis of a chiral nanographene constructed by five HBC units.
Scheme 16: Synthesis of a chiral nanographene constructed by seven HBC units.
Beilstein J. Org. Chem. 2023, 19, 700–718, doi:10.3762/bjoc.19.51
Graphical Abstract
Figure 1: Dibenzo[b,f]azepine (1a), -oxepine (1b) and -thiepine (1c) as examples of dibenzo[b,f]heteropines (1...
Figure 2: Selected pharmaceuticals with the dibenzo[b,f]azepine skeleton.
Figure 3: Examples of 10,11-dihydrodibenzo[b,f]azepine-based ligands.
Figure 4: The dibenzo[b,f]azepine moiety in dyes with properties suitable for the use in organic light emitti...
Figure 5: Selective bioactive natural products (13–18) containing the dibenzo[b,f]oxepine scaffold and Novart...
Scheme 1: Retrosynthetic approach to 5H-dibenzo[b,f]azepine (1a) from nitrotoluene (22).
Scheme 2: Oxidative coupling of o-nitrotoluene (22) and reduction of 2,2'-dinitrobibenzyl (21) to form 2,2'-d...
Scheme 3: Synthesis of 10,11-dihydro-5H-dibenzo[b,f]azepine (2a) via amine condensation.
Scheme 4: Catalytic reduction of 10,11-dihydro-5H-dibenzo[b,f]azepine (2a).
Scheme 5: The Wagner–Meerwein rearrangement of acridin-9-ylmethanol (23) into 5H-dibenzo[b,f]azepine (1a).
Scheme 6: Oxidative ring expansion of 2-(9-xanthenyl)malonates 24.
Scheme 7: Ring expansion via C–H functionalisation.
Scheme 8: The synthesis of fluorinated 5H-dibenzo[b,f]azepine 38 from isatin (32).
Scheme 9: The synthesis of substituted dibenzo[b,f]azepines 43 from indoles 39.
Scheme 10: Retrosynthetic pathways to dibenzo[b,f]azepines via Buchwald–Hartwig amination.
Scheme 11: Synthesis of dibenzo[b,f]oxepine 54 and -azepine 55 derivatives via (i) Heck reaction and (ii) Buch...
Scheme 12: Double Buchwald–Hartwig amination and thioetherification in the synthesis of tricyclic azepines 60 ...
Scheme 13: Double Buchwald–Hartwig amination towards substituted dibenzoazepines 62.
Scheme 14: Double Buchwald–Hartwig amination towards 10,11-dihydro-5H-dibenzo[b,f]azepine derivatives 71.
Scheme 15: One-pot Suzuki coupling–Buchwald–Hartwig amination.
Scheme 16: One-pot Rh/Pd-catalysed synthesis of dihydropyridobenzazepines.
Scheme 17: A retrosynthetic pathway to dibenzo[b,f]azepines via Mizoroki–Heck reaction.
Scheme 18: One-pot domino Pd-catalyzed Mizoroki–Heck–Buchwald–Hartwig synthesis of dibenzo[b,f]azepines.
Scheme 19: Dibenzo[b,f]thiapine and -oxepine synthesis via SNAr (thio)etherification, Wittig methylenation and...
Scheme 20: A retrosynthetic pathway to dibenzo[b,f]oxepines via Ullmann coupling.
Scheme 21: Ullmann-type coupling in dibenzo[b,f]oxepine synthesis.
Scheme 22: Wittig reaction and Ullmann coupling as key steps in dihydrobenz[b,f]oxepine synthesis.
Scheme 23: Pd-catalysed dibenzo[b,f]azepine synthesis via norbornene azepine intermediate 109.
Scheme 24: A simple representation of olefin metathesis resulting in transalkylidenation.
Scheme 25: Ring-closing metathesis as key step in the synthesis of dibenzo[b,f]heteropines.
Scheme 26: Alkyne–aldehyde metathesis in the synthesis of dibenzo[b,f]heteropines.
Scheme 27: Hydroarylation of 9-(2-alkynylphenyl)-9H-carbazole derivatives.
Scheme 28: Oxidative coupling of bisphonium ylide intermediate to give pacharin (13).
Scheme 29: Preparation of 10,11-dihydrodibenzo[b,f]heteropines via intramolecular Wurtz reaction.
Scheme 30: Phenol deprotonation and intramolecular etherification in the synthesis of bauhinoxepine J.
Figure 6: Functionalisation of dibenzo[b,f]azepine.
Scheme 31: Palladium-catalysed N-arylation of dibenzo[b,f]azepine.
Scheme 32: Cu- and Ni-catalysed N-arylation.
Scheme 33: N-Alkylation of dibenzo[b,f]azepine (1a) and dihydrodibenzo[b,f]azepine (2a).
Scheme 34: Preparation of methoxyiminosilbene.
Scheme 35: Synthesis of oxcarbazepine (153) from methoxy iminostilbene 151.
Scheme 36: Ring functionalisation of dihydrodibenzo[b,f]azepine.
Beilstein J. Org. Chem. 2023, 19, 566–574, doi:10.3762/bjoc.19.41
Graphical Abstract
Scheme 1: Selected examples of the chiral ligands used for synthesis of the Ni(II)–Schiff base complexes.
Scheme 2: Synthesis of the chiral ligand L7 and its Ni(II) complexes with glycine, serine, dehydroalanine, an...
Figure 1: Fragment of the NOESY spectrum of the ʟ-(oBrCysNi)L7 complex indicating the correlation between the...
Figure 2: Low-gradient isosurfaces with low densities (blue color of the isosurface corresponds to the hydrog...
Figure 3: Saturated solutions of (GlyNi)L1 (left) and (GlyNi)L7 (right) in diethyl ether.
Figure 4: The CV curves observed for (GlyNi)L7 and (ΔAlaNi)L7 in the anodic and cathodic regions (Pt, CH3CN, ...
Beilstein J. Org. Chem. 2021, 17, 2848–2893, doi:10.3762/bjoc.17.196
Graphical Abstract
Figure 1: Price comparison among iron and other transition metals used in catalysis.
Scheme 1: Typical modes of C–C bond formation.
Scheme 2: The components of an iron-catalyzed domino reaction.
Scheme 3: Iron-catalyzed tandem cyclization and cross-coupling reactions of iodoalkanes 1 with aryl Grignard ...
Scheme 4: Three component iron-catalyzed dicarbofunctionalization of vinyl cyclopropanes 14.
Scheme 5: Three-component iron-catalyzed dicarbofunctionalization of alkenes 21.
Scheme 6: Double carbomagnesiation of internal alkynes 31 with alkyl Grignard reagents 32.
Scheme 7: Iron-catalyzed cycloisomerization/cross-coupling of enyne derivatives 35 with alkyl Grignard reagen...
Scheme 8: Iron-catalyzed spirocyclization/cross-coupling cascade.
Scheme 9: Iron-catalyzed alkenylboration of alkenes 50.
Scheme 10: N-Alkyl–N-aryl acrylamide 60 CDC cyclization with C(sp3)–H bonds adjacent to a heteroatom.
Scheme 11: 1,2-Carboacylation of activated alkenes 60 with aldehydes 65 and alcohols 67.
Scheme 12: Iron-catalyzed dicarbonylation of activated alkenes 68 with alcohols 67.
Scheme 13: Iron-catalyzed cyanoalkylation/radical dearomatization of acrylamides 75.
Scheme 14: Synergistic photoredox/iron-catalyzed 1,2-dialkylation of alkenes 82 with common alkanes 83 and 1,3...
Scheme 15: Iron-catalyzed oxidative coupling/cyclization of phenol derivatives 86 and alkenes 87.
Scheme 16: Iron-catalyzed carbosulfonylation of activated alkenes 60.
Scheme 17: Iron-catalyzed oxidative spirocyclization of N-arylpropiolamides 91 with silanes 92 and tert-butyl ...
Scheme 18: Iron-catalyzed free radical cascade difunctionalization of unsaturated benzamides 94 with silanes 92...
Scheme 19: Iron-catalyzed cyclization of olefinic dicarbonyl compounds 97 and 100 with C(sp3)–H bonds.
Scheme 20: Radical difunctionalization of o-vinylanilides 102 with ketones and esters 103.
Scheme 21: Dehydrogenative 1,2-carboamination of alkenes 82 with alkyl nitriles 76 and amines 105.
Scheme 22: Iron-catalyzed intermolecular 1,2-difunctionalization of conjugated alkenes 107 with silanes 92 and...
Scheme 23: Four-component radical difunctionalization of chemically distinct alkenes 114/115 with aldehydes 65...
Scheme 24: Iron-catalyzed carbocarbonylation of activated alkenes 60 with carbazates 117.
Scheme 25: Iron-catalyzed radical 6-endo cyclization of dienes 119 with carbazates 117.
Scheme 26: Iron-catalyzed decarboxylative synthesis of functionalized oxindoles 130 with tert-butyl peresters ...
Scheme 27: Iron‑catalyzed decarboxylative alkylation/cyclization of cinnamamides 131/134.
Scheme 28: Iron-catalyzed carbochloromethylation of activated alkenes 60.
Scheme 29: Iron-catalyzed trifluoromethylation of dienes 142.
Scheme 30: Iron-catalyzed, silver-mediated arylalkylation of conjugated alkenes 115.
Scheme 31: Iron-catalyzed three-component carboazidation of conjugated alkenes 115 with alkanes 101/139b and t...
Scheme 32: Iron-catalyzed carboazidation of alkenes 82 and alkynes 160 with iodoalkanes 20 and trimethylsilyl ...
Scheme 33: Iron-catalyzed asymmetric carboazidation of styrene derivatives 115.
Scheme 34: Iron-catalyzed carboamination of conjugated alkenes 115 with alkyl diacyl peroxides 163 and acetoni...
Scheme 35: Iron-catalyzed carboamination using oxime esters 165 and arenes 166.
Scheme 36: Iron-catalyzed iminyl radical-triggered [5 + 2] and [5 + 1] annulation reactions with oxime esters ...
Scheme 37: Iron-catalyzed decarboxylative alkyl etherification of alkenes 108 with alcohols 67 and aliphatic a...
Scheme 38: Iron-catalyzed inter-/intramolecular alkylative cyclization of carboxylic acid and alcohol-tethered...
Scheme 39: Iron-catalyzed intermolecular trifluoromethyl-acyloxylation of styrene derivatives 115.
Scheme 40: Iron-catalyzed carboiodination of terminal alkenes and alkynes 180.
Scheme 41: Copper/iron-cocatalyzed cascade perfluoroalkylation/cyclization of 1,6-enynes 183/185.
Scheme 42: Iron-catalyzed stereoselective carbosilylation of internal alkynes 187.
Scheme 43: Synergistic photoredox/iron catalyzed difluoroalkylation–thiolation of alkenes 82.
Scheme 44: Iron-catalyzed three-component aminoazidation of alkenes 82.
Scheme 45: Iron-catalyzed intra-/intermolecular aminoazidation of alkenes 194.
Scheme 46: Stereoselective iron-catalyzed oxyazidation of enamides 196 using hypervalent iodine reagents 197.
Scheme 47: Iron-catalyzed aminooxygenation for the synthesis of unprotected amino alcohols 200.
Scheme 48: Iron-catalyzed intramolecular aminofluorination of alkenes 209.
Scheme 49: Iron-catalyzed intramolecular aminochlorination and aminobromination of alkenes 209.
Scheme 50: Iron-catalyzed intermolecular aminofluorination of alkenes 82.
Scheme 51: Iron-catalyzed aminochlorination of alkenes 82.
Scheme 52: Iron-catalyzed phosphinoylazidation of alkenes 108.
Scheme 53: Synergistic photoredox/iron-catalyzed three-component aminoselenation of trisubstituted alkenes 82.
Beilstein J. Org. Chem. 2020, 16, 1754–1804, doi:10.3762/bjoc.16.147
Graphical Abstract
Figure 1: Concept of dual synergistic catalysis.
Figure 2: Classification of catalytic systems involving two catalysts.
Figure 3: General mechanism for the dual nickel/photoredox catalytic system.
Figure 4: General mechanisms for C–H activation catalysis involving different reoxidation strategies.
Figure 5: Indole synthesis via dual C–H activation/photoredox catalysis.
Figure 6: Proposed mechanism for the indole synthesis via dual catalysis.
Figure 7: Oxidative Heck reaction on arenes via the dual catalysis.
Figure 8: Proposed mechanism for the Heck reaction on arenes via dual catalysis.
Figure 9: Oxidative Heck reaction on phenols via the dual catalysis.
Figure 10: Proposed mechanism for the Heck reaction on phenols via dual catalysis.
Figure 11: Carbazole synthesis via dual C–H activation/photoredox catalysis.
Figure 12: Proposed mechanism for the carbazole synthesis via dual catalysis.
Figure 13: Carbonylation of enamides via the dual C–H activation/photoredox catalysis.
Figure 14: Proposed mechanism for carbonylation of enamides via dual catalysis.
Figure 15: Annulation of benzamides via the dual C–H activation/photoredox catalysis.
Figure 16: Proposed mechanism for the annulation of benzamides via dual catalysis.
Figure 17: Synthesis of indoles via the dual C–H activation/photoredox catalysis.
Figure 18: Proposed mechanism for the indole synthesis via dual catalysis.
Figure 19: General concept of dual catalysis merging C–H activation and photoredox catalysis.
Figure 20: The first example of dual catalysis merging C–H activation and photoredox catalysis.
Figure 21: Proposed mechanism for the C–H arylation with diazonium salts via dual catalysis.
Figure 22: Dual catalysis merging C–H activation/photoredox using diaryliodonium salts.
Figure 23: Direct arylation via the dual catalytic system reported by Xu.
Figure 24: Direct arylation via dual catalytic system reported by Balaraman.
Figure 25: Direct arylation via dual catalytic system reported by Guo.
Figure 26: C(sp3)–H bond arylation via the dual Pd/photoredox catalytic system.
Figure 27: Acetanilide derivatives acylation via the dual C–H activation/photoredox catalysis.
Figure 28: Proposed mechanism for the C–H acylation with α-ketoacids via dual catalysis.
Figure 29: Acylation of azobenzenes via the dual catalysis C–H activation/photoredox.
Figure 30: C2-acylation of indoles via the dual C–H activation/photoredox catalysis.
Figure 31: Proposed mechanism for the C2-acylation of indoles with aldehydes via dual catalysis.
Figure 32: C2-acylation of indoles via the dual C–H activation/photoredox catalysis.
Figure 33: Perfluoroalkylation of arenes via the dual C–H activation/photoredox catalysis.
Figure 34: Proposed mechanism for perfluoroalkylation of arenes via dual catalysis.
Figure 35: Sulfonylation of 1-naphthylamides via the dual C–H activation/photoredox catalysis.
Figure 36: Proposed mechanism for sulfonylation of 1-naphthylamides via dual catalysis.
Figure 37: meta-C–H Alkylation of arenes via visible-light metallaphotocatalysis.
Figure 38: Alternative procedure for meta-C–H alkylation of arenes via metallaphotocatalysis.
Figure 39: Proposed mechanism for meta-C–H alkylation of arenes via metallaphotocatalysis.
Figure 40: C–H borylation of arenes via visible-light metallaphotocatalysis.
Figure 41: Proposed mechanism for C–H borylation of arenes via visible-light metallaphotocatalysis.
Figure 42: Undirected C–H aryl–aryl cross coupling via dual gold/photoredox catalysis.
Figure 43: Proposed mechanism for the undirected C–H aryl–aryl cross-coupling via dual catalysis.
Figure 44: Undirected C–H arylation of (hetero)arenes via dual manganese/photoredox catalysis.
Figure 45: Proposed mechanism for the undirected arylation of (hetero)arenes via dual catalysis.
Figure 46: Photoinduced C–H arylation of azoles via copper catalysis.
Figure 47: Photo-induced C–H chalcogenation of azoles via copper catalysis.
Figure 48: Decarboxylative C–H adamantylation of azoles via dual cobalt/photoredox catalysis.
Figure 49: Proposed mechanism for the C–H adamantylation of azoles via dual catalysis.
Figure 50: General mechanisms for the “classical” (left) and Cu-free variant (right) Sonogoshira reaction.
Figure 51: First example of a dual palladium/photoredox catalysis for Sonogashira-type couplings.
Figure 52: Arylation of terminal alkynes with diazonium salts via dual gold/photoredox catalysis.
Figure 53: Proposed mechanism for the arylation of terminal alkynes via dual catalysis.
Figure 54: C–H Alkylation of alcohols promoted by H-atom transfer (HAT).
Figure 55: Proposed mechanism for the C–H alkylation of alcohols promoted by HAT.
Figure 56: C(sp3)–H arylation of latent nucleophiles promoted by H-atom transfer.
Figure 57: Proposed mechanism for the C(sp3)–H arylation of latent nucleophiles promoted by HAT.
Figure 58: Direct α-arylation of alcohols promoted by H-atom transfer.
Figure 59: Proposed mechanism for the direct α-arylation of alcohols promoted by HAT.
Figure 60: C–H arylation of amines via dual Ni/photoredox catalysis.
Figure 61: Proposed mechanism for the C–H arylation of amines via dual Ni/photoredox catalysis.
Figure 62: C–H functionalization of nucleophiles via excited ketone/nickel dual catalysis.
Figure 63: Proposed mechanism for the C–H functionalization enabled by excited ketones.
Figure 64: Selective sp3–sp3 cross-coupling promoted by H-atom transfer.
Figure 65: Proposed mechanism for the selective sp3–sp3 cross-coupling promoted by HAT.
Figure 66: Direct C(sp3)–H acylation of amines via dual Ni/photoredox catalysis.
Figure 67: Proposed mechanism for the C–H acylation of amines via dual Ni/photoredox catalysis.
Figure 68: C–H hydroalkylation of internal alkynes via dual Ni/photoredox catalysis.
Figure 69: Proposed mechanism for the C–H hydroalkylation of internal alkynes.
Figure 70: Alternative procedure for the C–H hydroalkylation of ynones, ynoates, and ynamides.
Figure 71: Allylic C(sp3)–H activation via dual Ni/photoredox catalysis.
Figure 72: Proposed mechanism for the allylic C(sp3)–H activation via dual Ni/photoredox catalysis.
Figure 73: Asymmetric allylation of aldehydes via dual Cr/photoredox catalysis.
Figure 74: Proposed mechanism for the asymmetric allylation of aldehydes via dual catalysis.
Figure 75: Aldehyde C–H functionalization promoted by H-atom transfer.
Figure 76: Proposed mechanism for the C–H functionalization of aldehydes promoted by HAT.
Figure 77: Direct C–H arylation of strong aliphatic bonds promoted by HAT.
Figure 78: Proposed mechanism for the C–H arylation of strong aliphatic bonds promoted by HAT.
Figure 79: Direct C–H trifluoromethylation of strong aliphatic bonds promoted by HAT.
Figure 80: Proposed mechanism for the C–H trifluoromethylation of strong aliphatic bonds.
Beilstein J. Org. Chem. 2020, 16, 1296–1304, doi:10.3762/bjoc.16.110
Graphical Abstract
Figure 1: Phthalimide derivatives 1–3 and the corresponding azomethine ylides 1AMY-3AMY.
Scheme 1: Irradiation of 1 in the presence of acrylonitrile (AN).
Figure 2: Dependence of the chemical shift of the H-atom at the cyclohexane 2 position in compound 2 on the β...
Scheme 2: Complexation of 2 with β-CD, and formation of a ternary complex AN@2@β-CD.
Scheme 3: Photochemistry of 2 in the presence of AN, with or without β-CD.
Scheme 4: Photochemistry of 3 in the presence of AN, with or without β-CD.
Beilstein J. Org. Chem. 2019, 15, 2664–2670, doi:10.3762/bjoc.15.259
Graphical Abstract
Scheme 1: Synthesis of compound 1.
Figure 1: X-ray structure of compound 1 (one of the two enantiomers present in the crystal).
Scheme 2: Possible mechanism for the formation of 1.
Figure 2: A possible mechanism for the trans-position of the methyne hydrogens in the azepine ring: the elect...
Figure 3: Selective formation of a single diastereomer in the 1,3-dipolar cycloaddition reaction.
Scheme 3: Synthesis of nitroxide 6.
Figure 4: X-ray structure of compound 6 (one of the two enantiomers present in the crystal).
Scheme 4: A proposed mechanism for nitroxide 6 synthesis.
Figure 5: A, B) Temperature dependence of the electron spin relaxation times in water/glycerol at X-band freq...
Beilstein J. Org. Chem. 2018, 14, 560–575, doi:10.3762/bjoc.14.43
Graphical Abstract
Scheme 1: Formation of amidoalkylnaphthols 4 via o-QM intermediate 3.
Scheme 2: Asymmetric syntheses of triarylmethanes starting from diarylmethylamines.
Scheme 3: Proposed mechanism for the formation of 2,2-dialkyl-3-dialkylamino-2,3-dihydro-1H-naphtho[2,1-b]pyr...
Scheme 4: Cycloadditions of isoflavonoid-derived o-QMs and various dienophiles.
Scheme 5: [4 + 2] Cycloaddition reactions between aminonaphthols and cyclic amines.
Scheme 6: Brønsted acid-catalysed reaction between aza-o-QMs and 2- or 3-substituted indoles.
Scheme 7: Formation of 3-(α,α-diarylmethyl)indoles 52 in different synthetic pathways.
Scheme 8: Alkylation of o-QMs with N-, O- or S-nucleophiles.
Scheme 9: Formation of DNA linkers and o-QM mediated polymers.
Beilstein J. Org. Chem. 2016, 12, 874–881, doi:10.3762/bjoc.12.86
Graphical Abstract
Figure 1: Selected examples of biologically active, fused 2,1-isoxazole derivatives.
Scheme 1: Photochemical cyclization of substituted 2-azidobenzoic acids and possible reaction mechanism [34-59].
Scheme 2: Proposed reaction mechanism of the base-mediated photochemical cyclization of 2-azidobenzoic acids.
Beilstein J. Org. Chem. 2015, 11, 1833–1864, doi:10.3762/bjoc.11.199
Graphical Abstract
Figure 1: Ruthenium alkylidene catalysts used in RRM processes.
Figure 2: General representation of various RRM processes.
Figure 3: A general mechanism for RRM process.
Scheme 1: RRM of cyclopropene systems.
Scheme 2: RRM of cyclopropene with catalyst 2. (i) catalyst 2 (2.5 mol %), ethylene (24, 1 atm), (ii) toluene...
Scheme 3: RRM of various cyclopropene derivatives with catalyst 2. (i) catalyst 2 (2.5 mol %), CH2Cl2 (c = 0....
Scheme 4: RRM of substituted cyclopropene system with catalyst 2.
Scheme 5: RRM of cyclobutene system with catalyst 2.
Scheme 6: RRM approach to various bicyclic compounds.
Scheme 7: RRM approach to erythrina alkaloid framework.
Scheme 8: ROM–RCM sequence to lactone derivatives.
Scheme 9: RRM protocol towards the synthesis of lactone derivative 58.
Scheme 10: RRM protocol towards the asymmetric synthesis of asteriscunolide D (61).
Scheme 11: RRM strategy towards the synthesis of various macrolide rings.
Scheme 12: RRM protocol to dipiperidine system.
Scheme 13: RRM of cyclopentene system to generate the cyclohexene systems.
Scheme 14: RRM of cyclopentene system 74.
Scheme 15: RRM approach to compound 79.
Scheme 16: RRM approach to spirocycles.
Scheme 17: RRM approach to bicyclic dihydropyrans.
Scheme 18: RCM–ROM–RCM cascade using non strained alkenyl heterocycles.
Scheme 19: First ROM–RCM–ROM–RCM cascade for the synthesis of trisaccharide 97.
Scheme 20: RRM of cyclohexene system.
Scheme 21: RRM approach to tricyclic spirosystem.
Scheme 22: RRM approach to bicyclic building block 108a.
Scheme 23: ROM–RCM protocol for the synthesis of the bicyclo[3.3.0]octene system.
Scheme 24: RRM protocol to bicyclic enone.
Scheme 25: RRM protocol toward the synthesis of the tricyclic system 118.
Scheme 26: RRM approach toward the synthesis of the tricyclic enones 122a and 122b.
Scheme 27: Synthesis of tricyclic and tetracyclic systems via RRM protocol.
Scheme 28: RRM protocol towards the synthesis of tetracyclic systems.
Scheme 29: RRM of the propargylamino[2.2.1] system.
Scheme 30: RRM of highly decorated bicyclo[2.2.1] systems.
Scheme 31: RRM protocol towards fused tricyclic compounds.
Scheme 32: RRM protocol to functionalized tricyclic systems.
Scheme 33: RRM approach to functionalized polycyclic systems.
Scheme 34: Sequential RRM approach to functionalized tricyclic ring system 166.
Scheme 35: RRM protocol to functionalized CDE tricyclic ring system of schintrilactones A and B.
Scheme 36: Sequential RRM approach to 7/5 fused bicyclic systems.
Scheme 37: Sequential ROM-RCM protocol for the synthesis of bicyclic sugar derivatives.
Scheme 38: ROM–RCM sequence of the norbornene derivatives 186 and 187.
Scheme 39: RRM approach toward highly functionalized bridge tricyclic system.
Scheme 40: RRM approach toward highly functionalized tricyclic systems.
Scheme 41: Synthesis of hexacyclic compound 203 by RRM approach.
Scheme 42: RRM approach toward C3-symmetric chiral trimethylsumanene 209.
Scheme 43: Triquinane synthesis via IMDA reaction and RRM protocol.
Scheme 44: RRM approach to polycyclic compounds.
Scheme 45: RRM strategy toward cis-fused bicyclo[3.3.0]carbocycles.
Scheme 46: RRM protocol towards the synthesis of bicyclic lactone 230.
Scheme 47: RRM approach to spiro heterocyclic compounds.
Scheme 48: RRM approach to spiro heterocyclic compounds.
Scheme 49: RRM approach to regioselective pyrrolizidine system 240.
Scheme 50: RRM approach to functionalized bicyclic derivatives.
Scheme 51: RRM approach to tricyclic derivatives 249 and 250.
Scheme 52: RRM approach to perhydroindoline derivative and spiro system.
Scheme 53: RRM approach to bicyclic pyran derivatives.
Scheme 54: RRM of various functionalized oxanorbornene systems.
Scheme 55: RRM to assemble the spiro fused-furanone core unit. (i) 129, benzene, 55 °C, 3 days; (ii) Ph3P=CH2B...
Scheme 56: RRM protocol to norbornenyl sultam systems.
Scheme 57: Ugi-RRM protocol for the synthesis of 2-aza-7-oxabicyclo system.
Scheme 58: Synthesis of spiroketal systems via RRM protocol.
Scheme 59: RRM approach to cis-fused heterotricyclic system.
Scheme 60: RRM protocol to functionalized bicyclic systems.
Scheme 61: ROM/RCM/CM cascade to generate bicyclic scaffolds.
Scheme 62: RCM of ROM/CM product.
Scheme 63: RRM protocol to bicyclic isoxazolidine ring system.
Scheme 64: RRM approach toward the total synthesis of (±)-8-epihalosaline (300).
Scheme 65: Sequential RRM approach to decalin 304 and 7/6 fused 305 systems.
Scheme 66: RRM protocol to various fused carbocyclic derivatives.
Scheme 67: RRM to cis-hydrindenol derivatives.
Scheme 68: RRM protocol towards the cis-hydrindenol derivatives.
Scheme 69: RRM approach toward the synthesis of diversed polycyclic lactams.
Scheme 70: RRM approach towards synthesis of hexacyclic compound 324.
Scheme 71: RRM protocol to generate luciduline precursor 327 with catalyst 2.
Scheme 72: RRM protocol to key building block 330.
Scheme 73: RRM approach towards the synthesis of key intermediate 335.
Scheme 74: RRM protocol to highly functionalized spiro-pyran system 339.
Scheme 75: RRM to various bicyclic polyether derivatives.
Beilstein J. Org. Chem. 2015, 11, 481–492, doi:10.3762/bjoc.11.54
Graphical Abstract
Scheme 1: The synthesis of N-monoallylated indigo derivatives.
Scheme 2: The synthesis of 8a-hydroxyazepinodiindolones.
Figure 1: The structure and X-ray crystal structure (ball and stick representation) of azepinodiindolone 7. T...
Figure 2: Dihydroazepino[1,2-a:3,4-b']diindolones from Nb-acyl-L-tryptophanamides [5].
Scheme 3: The optimal synthesis of spiro heterocycles 12–16, and spiro/polyfused ring heterocycles 17 and 18 ...
Scheme 4: The synthesis of the oxa-bridged azepinodiindolone 22 from indigo and 1-bromo-3-methylbut-2-ene.
Figure 3: Modelled structure (Spartan 10, v1.1.0, Wavefunction Inc) of bridged indigo-tetrahydrofuran product ...
Scheme 5: The reaction of indigo with cinnamyl bromide yielding two spiro-based derivatives.
Figure 4: Structural analysis of compound 23. Left: modelled structure showing the cisoid configuration of th...
Scheme 6: Proposed mechanism for the synthesis of the red diindolone heterocycles and the azepinodiindolones.
Scheme 7: Proposed mechanism for the formation of 22. The order of protonation and allylation is undetermined....
Scheme 8: Proposed mechanism for the formation of 23 from intermediate 29.
Scheme 9: Proposed key branch points and mechanistic sinks in the base-catalysed cascade allylation reactions...
Scheme 10: Reaction of the spiro heterocycle 12 with Grubbs' II catalyst, and X-ray crystal structure of the n...
Beilstein J. Org. Chem. 2013, 9, 2910–2915, doi:10.3762/bjoc.9.327
Graphical Abstract
Figure 1: Balanol (1) and ophiocordin (2).
Figure 2: Strategic bond disconnections of balanol.
Scheme 1: Synthesis of the benzophenone fragment of balanol.
Scheme 2: Synthesis of the hexahydroazepine core of balanol.
Scheme 3: Synthesis of balanol and an analogue.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2012, 8, 2025–2052, doi:10.3762/bjoc.8.229
Graphical Abstract
Figure 1: An immersion-well batch reactor with 125 W medium pressure Hg lamp.
Figure 2: Transmission profile of a 0.05 M solution, ε = 200 M−1 cm−1.
Figure 3: Schematic of a typical microflow photochemical reactor (above) and detail of a triple-channel micro...
Figure 4: Schematic of a typical macroflow photochemical reactor (above) and images of the FEP photochemical ...
Scheme 1: [2 + 2] photocycloadditions of enones with enol derivatives.
Scheme 2: Competing reactions in an intramolecular [2 + 2] photocycloaddition.
Scheme 3: Diastereocontrolled cycloaddition of a cyclic enone with cyclopentene.
Scheme 4: Comparison of yields and reaction times for a batch reactor with a microflow system.
Scheme 5: Intramolecular [2 + 2] photocycloaddition.
Scheme 6: Paterno–Büchi reaction of benzophenone with an allylic alcohol.
Scheme 7: Photooxygenation of cyclopentadiene.
Scheme 8: Preparation of the anthelmintic ascaridole 23.
Scheme 9: Production of rose oxide 27 from (−)-β-citronellol (24).
Scheme 10: Photocatalytic alkylation of benzylamine.
Scheme 11: Photocatalytic reduction of 4-nitroacetophenone.
Scheme 12: Conversion of L-lysine to L-pipecolinic acid.
Scheme 13: Photocatalytic hydrodehalogenation.
Scheme 14: Photocatalytic aza-Henry reactions.
Scheme 15: Photocatalytic α-alkylation of aliphatic ketones.
Scheme 16: Decarboxylative photochemical additions.
Scheme 17: Photochemical addition of isopropanol to furanones.
Scheme 18: Photochemical addition of methanol to limonene.
Scheme 19: Light-promoted reduction of flavone.
Scheme 20: Photoreduction of benzophenone with benzhydrol.
Scheme 21: Barton reaction in a microflow system.
Scheme 22: Microflow synthesis of vitamin D3.
Scheme 23: photochemical chlorination of cyclohexane.
Scheme 24: photochemical cyanation of pyrene.
Scheme 25: Intermolecular [2 + 2] cycloaddition of maleimide (76) and intramolecular [2 + 2] cycloaddition of ...
Scheme 26: Intramolecular [5 + 2] cycloaddition of maleimide under flow conditions.
Scheme 27: Intramolecular [5 + 2] cycloaddition as a key step in the synthesis of (±)-neostenine.
Scheme 28: In situ generation of a thioaldehyde by photolysis of a phenacyl sulfide.
Scheme 29: Photodimerisation of maleic anhydride.
Scheme 30: [2 + 2] cycloaddition of a chiral enone with ethylene.
Scheme 31: Intramolecular [2 + 2] cycloaddition of a cyclopentenone.
Scheme 32: Photochemical Wolff rearrangement and cyclisation to β-lactams.
Scheme 33: Photochemical rearrangement of aryl azides.
Scheme 34: Rearrangement of quinoline N-oxides to quinolones.
Scheme 35: Photochemical rearrangement of cyclobutenones.
Scheme 36: Photoisomerisation en route to a vitamin-D derivative.
Scheme 37: Schematic of the Seeberger photooxygenation apparatus and sensitised photooxygenation of citronello...
Scheme 38: Sensitised photooxygenation of dihydroartemisinic acid.
Scheme 39: Photochemical preparation of CpRu(MeCN)3PF6.
Scheme 40: In situ photochemical generation and reaction of a [CpRu]+ catalyst.
Scheme 41: Intermolecular alkene–alkyne coupling with photogenerated catalyst.
Scheme 42: PET deoxygenation of nucleosides.
Scheme 43: Photochemical defluorination of DABFT.
Scheme 44: Aromatic azide reduction by visible-light-mediated photocatalysis.
Scheme 45: Examples of visible-light-mediated reactions.
Scheme 46: Visible-light-mediated formation of iminium ions.
Scheme 47: Examples of visible-light-mediated photocatalytic reactions.
Scheme 48: Anhydride formation from a visible-light-mediated process.
Scheme 49: Light-mediated conjugate addition of glycosyl bromide 141 to acrolein.
Scheme 50: Visible-light-mediated photocyclisation to [5]helicene.
Beilstein J. Org. Chem. 2011, 7, 1713–1721, doi:10.3762/bjoc.7.201
Graphical Abstract
Scheme 1: Valence isomerization of cyclohepta-1,3,5-triene (1) and its heteroelement analogues.
Scheme 2: Conformational ring inversions.
Scheme 3: Rearrangements of the parent cycloheptatriene 1 and norcaradiene 2.
Figure 1: NICS(0) values of fluorinated heteropines.
Scheme 4: Reactivity of oxepine (3) and benzene oxide (4).
Figure 2: Stabilized thiepines 15–18.
Scheme 5: Valence isomerization of 1H-azepines.
Scheme 6: Reactivity of 1H-azepine.
Figure 3: Benzannulated azepines 27 and 28.
Figure 4: Reported phosphepines 29–32.
Scheme 7: Phosphinidene generation from metal-complexed benzophosphepine 33.
Beilstein J. Org. Chem. 2011, 7, 1468–1474, doi:10.3762/bjoc.7.170
Graphical Abstract
Scheme 1: Pd-catalyzed cyclization of N-allyl-pyrrole-2-carboxamides.
Figure 1: Significant relationships among hydrogen and carbon atoms arising from 2D-NMR studies to determine ...
Scheme 2: Proposed mechanism for the formation of the six-membered products.
Beilstein J. Org. Chem. 2011, 7, 1124–1129, doi:10.3762/bjoc.7.129
Graphical Abstract
Scheme 1: Products of aryl azide photolysis.
Scheme 2: Optimisation of the photolysis of aryl azide 8a.
Figure 1: Relationship between residence time and relative composition of the crude reaction mixture.
Scheme 3: Preparation of side product 10.
Scheme 4: General conditions for the photolysis of aryl azides in continuous flow.
Beilstein J. Org. Chem. 2011, 7, 1075–1094, doi:10.3762/bjoc.7.124
Graphical Abstract
Scheme 1: AuCl3-catalyzed benzannulations reported by Yamamoto.
Scheme 2: Synthesis of 9-oxabicyclo[3.3.1]nona-4,7-dienes from 1-oxo-4-oxy-5-ynes [40].
Scheme 3: Stereocontrolled oxacyclization/(4 + 2)-cycloaddition cascade of ketone–allene substrates [43].
Scheme 4: Gold-catalyzed synthesis of polycyclic, fully substituted furans from 1-(1-alkynyl)cyclopropyl keto...
Scheme 5: Gold-catalyzed 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with nitrones [47].
Scheme 6: Enantioselective 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with nitrones [48].
Scheme 7: Gold-catalyzed 1,3-dipolar cycloaddition of 2-(1-alkynyl)-2-alken-1-ones with α,β-unsaturated imine...
Scheme 8: Gold-catalyzed (4 + 3) cycloadditions of 1-(1-alkynyl)oxiranyl ketones [50].
Scheme 9: (3 + 2) Cycloaddition of gold-containing azomethine ylides [52].
Scheme 10: Gold-catalyzed generation and reaction of azomethine ylides [53].
Scheme 11: Gold-catalyzed intramolecular (4 + 2) cycloadditions of unactivated alkynes and dienes [55].
Scheme 12: Gold-catalyzed preparation of bicyclo[4.3.0]nonane derivatives from dienol silyl ethers [59].
Scheme 13: Gold(I)-catalyzed intramolecular (4 + 2) cycloadditions of arylalkynes or 1,3-enynes with alkenes [60].
Scheme 14: Gold(I)-catalyzed intermolecular (2 + 2) cycloaddition of alkynes with alkenes [62].
Scheme 15: Metal-catalyzed cycloaddition of alkynes tethered to cycloheptatriene [65].
Scheme 16: Gold-catalyzed cycloaddition of functionalized ketoenynes: Synthesis of (+)-orientalol F [68].
Scheme 17: Gold-catalyzed intermolecular cyclopropanation of enynes with alkenes [70].
Scheme 18: Gold-catalyzed intermolecular hetero-dehydro Diels–Alder cycloaddition [72].
Figure 1: Gold-catalyzed 1,2- or 1,3-acyloxy migrations of propargyl esters.
Scheme 19: Gold(I)-catalyzed stereoselective olefin cyclopropanation [74].
Scheme 20: Reaction of propargylic benzoates with α,β-unsaturated imines to give azepine cycloadducts [77].
Scheme 21: Gold-catalyzed (3 + 3) annulation of azomethine imines with propargyl esters [81].
Scheme 22: Gold(I)-catalyzed isomerization of 5-en-2-yn-1-yl acetates [83].
Scheme 23: (3 + 2) and (2 + 2) cycloadditions of indole-3-acetates 41 [85,86].
Scheme 24: Gold(I)-catalyzed (2 + 2) cycloaddition of allenenes [87].
Scheme 25: Formal (3 + 2) cycloaddition of allenyl MOM ethers and alkenes [90].
Scheme 26: (4 + 3) Cycloadditions of allenedienes [97,98].
Scheme 27: Gold-catalyzed transannular (4 + 3) cycloaddition reactions [101].
Scheme 28: Gold(I)-catalyzed (4 + 2) cycloadditions of allenedienes [102].
Scheme 29: Enantioselective gold(I)-catalyzed (4 + 2) cycloadditions of allenedienes [88,102,104].
Scheme 30: (3 + 2) versus (2 + 2) Cycloadditions of allenenes [87,99].
Figure 2: NHC ligands with different π-acceptor properties [106].
Scheme 31: (3 + 2) versus (2 + 2) Cycloadditions of allenenes [106].
Scheme 32: Gold(I)-catalyzed intermolecular (4 + 2) cycloaddition of allenamides and acyclic dienes [109].
Beilstein J. Org. Chem. 2011, 7, 951–959, doi:10.3762/bjoc.7.106
Graphical Abstract
Figure 1: Azepine frameworks found in natural products and pharmaceuticals.
Figure 2: Semihollow-shaped triethynylphosphine L1.
Figure 3: Time–conversion profiles for the gold-catalyzed cyclization of 4a with L1, X-Phos and IPr ligands.
Scheme 1: 8-exo-dig cyclization of sulfonamide 9.
Scheme 2: Isomerization experiments of 6a.
Figure 4: Possible pathway for the gold-catalyzed conversion of 4a into 5a.
Beilstein J. Org. Chem. 2011, 7, 897–936, doi:10.3762/bjoc.7.103
Graphical Abstract
Scheme 1: Gold-catalyzed addition of alcohols.
Scheme 2: Gold-catalyzed cycloaddition of alcohols.
Scheme 3: Ionic liquids as the solvent in gold-catalyzed cycloaddition.
Scheme 4: Gold-catalyzed cycloaddition of diynes.
Scheme 5: Gold(I) chloride catalyzed cycloisomerization of 2-alkynyl-1,5-diols.
Scheme 6: Gold-catalyzed cycloaddition of glycols and dihydroxy compounds.
Scheme 7: Gold-catalyzed ring-opening of cyclopropenes.
Scheme 8: Gold-catalyzed intermolecular hydroalkoxylation of alkynes. PR3 = 41–45.
Scheme 9: Gold-catalyzed intramolecular 6-endo-dig cyclization of β-hydroxy-α,α-difluoroynones.
Scheme 10: Gold-catalyzed intermolecular hydroalkoxylation of non-activated olefins.
Scheme 11: Preparation of unsymmetrical ethers from alcohols.
Scheme 12: Expedient synthesis of dihydrofuran-3-ones.
Scheme 13: Catalytic approach to functionalized divinyl ketones.
Scheme 14: Gold-catalyzed glycosylation.
Scheme 15: Gold-catalyzed cycloaddition of aldehydes and ketones.
Scheme 16: Gold-catalyzed annulations of 2-(ynol)aryl aldehydes and o-alkynyl benzaldehydes.
Scheme 17: Gold-catalyzed addition of carboxylates.
Scheme 18: Dual-catalyzed rearrangement reaction of allenoates.
Scheme 19: Meyer–Schuster rearrangement of propargylic alcohols.
Scheme 20: Propargylic alcohol rearrangements.
Scheme 21: Gold-catalyzed synthesis of imines and amine alkylation.
Scheme 22: Hydroamination of allenes and allenamides.
Scheme 23: Gold-catalyzed inter- and intramolecular amination of alkynes and alkenes.
Scheme 24: Gold-catalyzed cycloisomerization of O-propioloyl oximes and β-allenylhydrazones.
Scheme 25: Intra- and intermolecular amination with ureas.
Scheme 26: Gold-catalyzed cyclization of ortho-alkynyl-N-sulfonylanilines and but-3-yn-1-amines.
Scheme 27: Gold-catalyzed piperidine ring synthesis.
Scheme 28: Ring expansion of alkylnyl cyclopropanes.
Scheme 29: Gold-catalyzed annulations of N-propargyl-β-enaminones and azomethine imines.
Scheme 30: Gold(I)-catalyzed cycloisomerization of aziridines.
Scheme 31: AuCl3/AgSbF6-catalyzed intramolecular amination of 2-(tosylamino)phenylprop-1-en-3-ols.
Scheme 32: Gold-catalyzed cyclization via a 7-endo-dig pathway.
Scheme 33: Gold-catalyzed synthesis of fused xanthines.
Scheme 34: Gold-catalyzed synthesis of amides and isoquinolines.
Scheme 35: Gold-catalyzed oxidative cross-coupling reactions of propargylic acetates.
Scheme 36: Gold-catalyzed nucleophilic addition to allenamides.
Scheme 37: Gold-catalyzed direct carbon–carbon bond coupling reactions.
Scheme 38: Gold-catalyzed C−H functionalization of indole/pyrrole heterocycles and non-activated arenes.
Scheme 39: Gold-catalyzed cycloisomerization of cyclic compounds.
Scheme 40: Gold-catalyzed cycloaddition of 1-aryl-1-allen-6-enes and propargyl acetates.
Scheme 41: Gold(I)-catalyzed cycloaddition with ligand-controlled regiochemistry.
Scheme 42: Gold(I)-catalyzed cycloaddition of dienes and enynes.
Scheme 43: Gold-catalyzed intramolecular cycloaddition of 3-alkoxy-1,5-enynes and 2,2-dipropargylmalonates.
Scheme 44: Gold-catalyzed intramolecular cycloaddition of 1,5-allenynes.
Scheme 45: Gold(I)-catalyzed cycloaddition of indoles.
Scheme 46: Gold-catalyzed annulation reactions.
Scheme 47: Gold–carbenoid induced cleavage of a sp3-hybridized C−H bond.
Scheme 48: Furan- and indole-based cascade reactions.
Scheme 49: Tandem process using aromatic alkynes.
Scheme 50: Gold-catalyzed cycloaddition of 1,3-dien-5-ynes.
Scheme 51: Gold-catalyzed cascade cyclization of diynes, propargylic esters, and 1,3-enynyl ketones.
Scheme 52: Tandem reaction of β-phenoxyimino ketones and alkynyl oxime ethers.
Scheme 53: Gold-catalyzed tandem cyclization of enynes, 2-(tosylamino)phenylprop-1-yn-3-ols, and allenoates.
Scheme 54: Cyclization of 2,4-dien-6-yne carboxylic acids.
Scheme 55: Gold(I)-catalyzed tandem cyclization approach to tetracyclic indolines.
Scheme 56: Gold-catalyzed tandem reactions of alkynes.
Scheme 57: Aminoarylation and oxyarylation of alkenes.
Scheme 58: Cycloaddition of 2-ethynylnitrobenzene with various alkenes.
Scheme 59: Gold-catalyzed tandem reactions of allenoates and alkynes.
Scheme 60: Gold-catalyzed asymmetric synthesis of 2,3-dihydropyrroles.
Scheme 61: Chiral [NHC–Au(I)]-catalyzed cyclization of enyne.
Scheme 62: Gold-catalyzed hydroaminations and hydroalkoxylations.
Scheme 63: Gold(I)-catalyzed asymmetric hydroalkoxylation of 1,3-dihydroxymethyl-2-alkynylbenzene chromium com...
Scheme 64: Gold-catalyzed synthesis of julolidine derivatives.
Scheme 65: Gold-catalyzed the synthesis of chiral fused heterocycles.
Scheme 66: Gold-catalyzed asymmetric reactions with 3,5-(t-Bu)2-4-MeO-MeOBIPHEP.
Scheme 67: Gold-catalyzed cyclization of o-(alkynyl) styrenes.
Scheme 68: Asymmetric gold(I)-catalyzed redox-neutral domino reactions of enynes.
Scheme 69: Gold(I)-catalyzed enantioselective polyene cyclization reaction.
Scheme 70: Gold(I)-catalyzed enantioselective synthesis of benzopyrans.
Scheme 71: Gold(I)-catalyzed enantioselective ring expansion of allenylcyclopropanols.
Beilstein J. Org. Chem. 2007, 3, No. 44, doi:10.1186/1860-5397-3-44
Graphical Abstract
Scheme 1: Synthesis of symmetrically α,α'-disubstituted hydroxylamines 1.
Scheme 2: Synthesis of unsymmetrically α,α'-disubstituted hydroxylamines 3.
Scheme 3: Synthesis of piperidines 15–16 and azepine 17. Reagents and conditions: a) Ac2O, THF, 1 h, rt for 8...
Scheme 4: Synthesis of indolizidines 21–22 and pyrroloazepine 23. Reaction conditions: a) Tf2O, Py, rt, 2 h; ...